Evidence for a Novel Binding Site Conformer of Aldose Reductase in Ligand-Bound State†

Journal of Molecular Biology

Volumn 369, Issue 1, 2007, Pages 186-197

  Steuber, Holger ^a   Zentgraf, Matthias ^a   La Motta, Concettina ^b   Sartini, Stefania ^b   Heine, Andreas ^a   Klebe, Gerhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

aldose reductase; binding site; induced fit interaction; protein flexibility; structure based drug design

Indexed keywords

ACETIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; ESTER DERIVATIVE; INDOLE; ISOTHIAZOLE DERIVATIVE; LIGAND; TOLRESTAT; TRYPTOPHAN;

ARTICLE; BINDING SITE; CATALYSIS; CONFORMATION; CRYSTAL STRUCTURE; ENZYME BINDING; LIGAND BINDING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 34247375160     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.03.021     Document Type: Article

References (35)

1. Davis A.M., Teague S.J., and Kleywegt G.J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. 42 (2003) 2718-2736
2. Blundell T., Jhoti H., and Abell C. High-throughput crystallography for lead discovery in drug design. Nature Rev. Drug Discov. 1 (2002) 45-54
3. Williams S.P., Kuyper L.F., and Pearce K.H. Recent applications of protein crystallography and structure-guided drug design. Curr. Opin. Chem. Biol. 9 (2005) 371-380
4. Lundqvist T. The devil is still in the details-driving early drug discovery forward with biophysical experimental methods. Curr. Opin. Drug Discov. 8 (2005) 513-519
5. Colletier J.P., Sanson B., Nachon F., Gabellieri E., Fattorusso C., Campiani G., and Weik M. Conformational flexibility in the peripheral site of torpedo californica acetylcholinesterase revealed by the complex structure with a bifunctional inhibitor. J. Am. Chem. Soc. 128 (2006) 4526-4527
6. Teague S.J. Implications of protein flexibility for drug discovery. Nature Rev. Drug Discov. 2 (2003) 527-540
7. Howard E.I., Sanishvili R., Cachau R.E., Mitschler A., Chevrier B., Barth P., et al. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A. Proteins 55 (2004) 792-804
8. El-Kabbani O., Wilson D.K., Petrash J.M., and Quiocho F.A. Structural features of the aldose reductase and aldehyde reductase inhibitor binding sites. Mol. Vis. 4 (1998) 19-25
9. Urzhumtsev A., Tete-Favier F., Mitschler A., Barbanton J., Barth P., Urzhumtseva L., et al. A "specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 5 (1997) 601-612
10. Steuber H., Zentgraf M., Podjarny A.D., Heine A., and Klebe G. High resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. J. Mol. Biol. 356 (2006) 45-56
11. Varnai P., Richards W., and Lyne P.D. Modelling the catalytic reaction in human aldose reductase. Proteins 37 (1999) 218-227
12. Cachau R., Howard E., Barth P., Mitschler A., Chevrier B., Lamour V., et al. Model of the catalytic mechanism of human aldose reductase based on quantum chemical calculations. J. Phys. IV France 10 (2000) 3-13
13. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
14. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Oxidative stress and stress-activated signalling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23 (2002) 599-622
15. Price S.A., Agthong S., Middlemas A.B., and Tomlinson D.R. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy-interactions with aldose reductase. Diabetes 53 (2004) 1851-1856
16. Suzuki L.A., Poot M., Gerrity R.G., and Bornfeldt K.E. Diabetes accelerates smoth muscle accumulation in lesions of atherosclerosis. Lack of direct growth-promoting effects of high glucose levels. Diabetes 50 (2001) 851-860
17. Nakamura J., Kasuya Y., Hamada Y., Nakashima E., Naruse K., Yasuda Y., et al. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologica 44 (2001) 480-487
18. Suzen S., and Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem. 10 (2003) 1329-1352
19. Da Settimo F., Primofiore G., La Motta C., Sartini S., Taliani S., Simorini F., et al. Naphtho [1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors. J. Med. Chem. 48 (2005) 6897-6907
20. Wilson D.K., Tarle I., Petrash J.M., and Quiocho F.A. Refined 1.8 Å structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc. Natl Acad. Sci. USA 90 (1993) 9847-9851
21. Steuber H., Zentgraf M., Gerlach C., Sotriffer C.A., Heine A., and Klebe G. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying conditions. J. Mol. Biol. 363 (2006) 174-187
22. El-Kabbani O., Darmanin C., Schneider T.R., Hazemann I., Ruiz F., Oka M., et al. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. Proteins 55 (2004) 805-813
23. Kinoshita T., Miyake H., Fujii T., Takakura S., and Goto T. The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat. Acta Crystallog. sect. D 58 (2002) 622-626
24. Ruiz F., Hazemann I., Mitschler A., Joachimiak A., Schneider T., Karplus M., and Podjarny A. The crystallographic structure of the aldose reductase-IDD 552 complex shows direct proton donation from tyrosine 48. Acta Crystallog. sect. D 60 (2004) 1347-1354
25. Hendlich M., Bergner A., Gunther J., and Klebe G. Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. J. Mol. Biol. 326 (2003) 99-110
26. Najmanovich R., Kuttner J., Sobolev V., and Edelman M. Side-chain flexibility in proteins upon ligand binding. Proteins 39 (2000) 261-268
27. Sotriffer C.A., Krämer O., and Klebe G. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Proteins 56 (2004) 52-66
28. Zentgraf, M., Steuber, H., Koch, C., La Motta, C., Sartini, S., Sotriffer, C. A. & Klebe, G. (2007). How reliable are current docking approaches for structure-based drug design? Angew. Chem. Int. Ed. Engl., in press.
29. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
30. Calderone V., Chevrier B., Van Zandt M., Lamour V., Howard E., Poterszman A., et al. The structure of human aldose reductase bound to the inhibitor IDD 384. Acta Crystallog. sect. D 56 (2000) 536-540
31. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D 54 (1998) 905-921
32. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallog. sect. D 61 (2005) 458-464
33. Sheldrick G.M., and Schneider T. SHELXL: high-resolution refinement. Methods Enzymol. 277 (1997) 319-343
34. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A 47 (1991) 110-119
35. Laskowski R., MacArthur M., Moss D., and Thornton J. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26 (1993) 283-291